11 February 2013
3QFY13 Results Update | Sector: Financials
Canara Bank
BSE Sensex
S&P CNX
19,485
5,904
Bloomberg
CBK IN
Equity Shares (m)
443.0
M. Cap. (INR b)/(USD b)
198/3.7
52-Week Range (INR)
566/306
1,6,12 Rel.Perf.(%)
-12/17/-25
CMP: INR446
TP: INR600
Buy
Financials & Valuation (INR b)
Y/E March
2013E 2014E 2015E
98.0
70.9
35.7
2.4
80.7
23.1
585.9
475.2
14.6
0.8
17.4
5.5
0.8
0.9
2.7
115.0
83.2
42.0
2.4
94.7
17.4
664.7
535.6
15.1
0.8
17.4
4.7
0.7
0.8
3.2
NII
79.1
OP
57.0
NP
29.0
NIM (%)
2.2
EPS (INR)
65.5
EPS Gr. (%)
-11.6
BV/Sh. (INR) 518.6
ABV/Sh. (INR) 431.2
ROE (%)
13.3
ROA (%)
0.7
Payout (%)
17.4
Valuations
P/E(X)
6.8
P/BV (X)
0.9
P/ABV (X)
1.0
Div. Yield (%)
2.2
Canara Bank's 3QFY13 PAT of ~INR7.1b (-19% YoY and +7% QoQ) was 6% above our
estimate of INR6.7b. Higher non-interest income (27% above estimate)
compensated for higher than expected provisions and tax rate. NII was 3% below
estimate (+4% YoY and +2% QoQ to INR19.9b) led by lower-than-expected loan
growth (flat both QoQ and YoY). NIMs calculated improved 4bp QoQ to 2.27% (in-
line est).
Key highlights:
Net slippages remained high at INR11b v/s INR12.8b in 2QFY13. GNPAs/NNPAs
grew 9%/12% QoQ and PCR, including write-offs stood at 61%.
CBK restructured loan of INR8.7b during the quarter. However, repayment of
INR12.5b, took cumulative restructured loans (facility-wise) to INR145b v/s
INR149b a quarter ago. OSRL stood at INR134b (6.1% of loans facility-wise).
Non core income (forex + trading + recoveries + MTM on investment) stood
at INR4.2b (v/s INR3.3b) in 3QFY13 and INR9.3b (v/s INR8b) in 9MFY13.
CASA deposits grew 8% YoY (down 3% QoQ) led by 8% YoY growth in SA
deposits (down 3% QoQ). CASA ratio improved marginally to 25%.
Valuation and view:
CBK has aggressively built up investment portfolio, leading
to higher share of trading (including AFS gains) in the profitability. With expected
revival of growth from FY14 onwards, asset reallocation will be positive for
margins, further, benefit on cost of funds (due to fall in above card rate deposits)
will aid margin improvement in FY14. RoA and RoE will be healthy at 0.8%/16%
over FY14-15E. Maintain
Buy.
Alpesh Mehta
(Alpesh.Mehta@MotilalOswal.com) + 91 22 3982 5415
Sohail Halai
(Sohail.Halai@motilaloswal.com)+ 91 22 3982 5430
Investors are advised to refer through disclosures made at the end of the Research Report.
1